| Biomarker ID | 58 |
| PMID | 15609297 |
| Year | 2005 |
| Biomarker | GalNAc-T3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (4.6 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(GALNT3):-O-glycan biosynthesis,O-linked glycosylation of mucins, Post-translational protein modif,Protein met,Interleukin-2 signaling pathwayabolismication |
| Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 18 patients with prostate cancer and 35 patients with Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.005 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues. GALNT3 expression was also calculated by immunohistochemistry of 5 BPH and 5 PCa Patients |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | GALNT3 |